Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fibromatosis, Gingival, 2 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Blood Specimen Collection 14Observation 13Gemcitabine 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × seribantumab × Gynecologic × Clear all
NCT01209195 2016-09-08

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
41 enrolled 14 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡